Cognito's Spectris AD slows Alzheimer's disease progression in trial
The device utilises non-invasive neuromodulation with synchronised light and sound at a gamma frequency to restore disrupted brain activity in Alzheimer's patients.
The study involved 76 mild-to-moderate affected subjects. It included a randomised six-month controlled phase and a subsequent 12-month open-label extension.
During the controlled phase, one-hour treatments with the device daily led to 4.83 months of preserved daily activity, 4.56 and 4.09 months of delayed cognitive decline and whole-brain atrophy, respectively.
Subjects who received the device's treatment showed a delay in progression of the disease compared to those in the sham treatment group.
Specifically, subjects initially assigned to Spectris AD and later treated with SPECTRIS in the open-label extension study showed a slower progression to the same degree of decline that the sham group experienced during six months.
Tailored for at-home use, Spectris AD has been granted breakthrough device designation by the US Food and Drug Administration (FDA) and is now under assessment in the HOPE pivotal trial.
Cognito Therapeutics CEO Christian Howell said: 'Our brains are electrical systems, and Alzheimer's disrupts the rhythms that govern memory, cognition, and our ability to function.
'Spectris AD represents a new class of therapy, one based in physics, that restores these natural neural oscillations without relying on a chemistry-based pharmacologic therapy. These findings show the potential to meaningfully slow disease progression by leveraging the potential of neuromodulation.'
Last year, Cognito enrolled the first subject in a biomarker substudy within the HOPE trial evaluating the sensory stimulation device in Alzheimer's patients.
"Cognito's Spectris AD slows Alzheimer's disease progression in trial" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why your body ages rapidly in two 'bursts'
When you buy through links on our articles, Future and its syndication partners may earn a commission. Have you ever woken up in the morning and suddenly felt old? There might be a good reason. A series of studies has found that, rather than ageing gradually on a linear timescale, we might have significant "bursts" of getting old during our adult years, said National Geographic. These two bursts usually happen in our mid-40s and our early-60s, according to a research team at Stanford University, who tracked thousands of different molecules in people aged 25 to 75. The researchers found that 81% of the molecules didn't change continuously, as you'd expect, but actually transformed significantly around certain ages. Their "provocative" findings seem to "fly in the face" of current models of ageing, said David Sinclair, a molecular geneticist, longevity researcher, and professor at Harvard Medical School. A separate study by a team in Germany last year found that sudden chemical modifications to DNA occurred in mice in early to mid-life and again in mid to late life, hinting that there were "three discrete stages of ageing", said The New York Times. And a 2019 analysis, which examined the blood plasma of over 4,000 people, found there were "significant jumps" in concentrations of proteins associated with ageing in the fourth, seventh and eighth decades of life. This "sudden ageing" can come with "an acceleration in muscle wastage and skin decline", said New Scientist, along with an inability to metabolise alcohol, a swift dwindling of immune cells, and substantial increases in the risk of cardiovascular disease and of dying. Although none of this sounds particularly enjoyable, the various findings "don't have to make you dread hitting your 40s and 60s", said National Geographic, because understanding "how and when we age" can help experts and the general public take "specific steps to prevent or at least prepare for" some of the "most undesirable" aspects of the process. The pattern "fits with previous evidence" that the threat of many age-related diseases does not "increase incrementally", said The Guardian. Conditions such as Alzheimer's and cardiovascular disease tend to show a "steep uptick" after 60. There is a note of caution to attach to the Stanford findings, said Sinclair, as other studies have found that people often experience a "mid-life crisis" in their late-30s and early-40s or a "late-life crisis" in their late-50s and early-60s – the two periods linked to the ageing "bursts". To put it another way, it's possible "associated psychological and lifestyle changes may be responsible for these changes in ageing and not due to our inherent biology".
Miami Herald
an hour ago
- Miami Herald
Can these things cure us? How leaders are tackling health issues in Miami
Health Care Can these things cure us? How leaders are tackling health issues in Miami These articles focus on innovative approaches to tackling health issues in Miami through community engagement, partnerships and technology. A new partnership involving electric cars aims to improve accessibility to prenatal and postpartum care in South Florida, addressing transportation challenges for pregnant women. To address Alzheimer's research, University of Miami researchers venture into local communities. Technology's role in health care receives attention as well. Innovations like high-intensity ultrasounds offer non-invasive cancer treatments at Memorial Healthcare System. Meanwhile, gene therapy at Jackson Health shows promise in alleviating symptoms of sickle cell disease, changing patient lives dramatically. Read the stories below to catch up. Marie Odvil uses a free car service for low-income pregnant mothers provided by Green Cars For Kids in partnership with Freebee and Jackson Health on Wednesday, Aug. 28, 2024, outside of Holtz Children's Hospital on Jackson's campus in Miami. By Alie Skowronski NO. 1: CAN A CAR RIDE HELP YOUR HEALTH? FOR SOUTH FLORIDA MATERNITY PATIENTS, IT'S AN ISSUE What to know about the transit services for mother and baby. | Published October 7, 2024 | Read Full Story by Michelle Marchante A caretaker, center, offers cafecito to Asustina Valdes Cabrera, left, while she is tested by UHealth medical researcher Dr. Katrina Celis, right, as part of an Alzheimer study during a community outreach event for the John P. Hussman Institute for Human Genomics where UM researchers performed tests, enrolled new participants and took blood samples to a new Biorespository opening at UHealth's campus, at Hora Feliz Adult Day Care on Thursday, January 16, 2025, in Hialeah, Fla. By D.A. Varela NO. 2: HOW A UM LAB IS UNLOCKING THE SECRETS OF THE BRAIN. IT STARTS WITH A PERSONAL MESSAGE What to know about the visits. | Published January 24, 2025 | Read Full Story by Michelle Marchante No image found Dr. Omar H. Llaguna, specialist in surgical oncology, looks at a medium that mimics a liver tumor in a human body to demonstrate how a histotripsy procedure works, performed by a HistoSonics medical device during a demonstration at the Memorial Hospital West, in Pembroke Pines, on Thursday June 12, 2025. By Pedro Portal NO. 3: 'LIFE JUST CHANGED.' HOW MIAMI DOCTORS USE TECH TO TREAT CANCER AND SICKLE CELL What to know about new ultrasound, editing genes and prosthetics. | Published June 19, 2025 | Read Full Story by Michelle Marchante No image found Dr. Juan Cendan, dean of FIU's Herbert Wertheim College of Medicine, speaks during a ceremony announcing the launch of a new clinical, research and academic collaboration between FIU and Nicklaus Children's Health System on Monday, May 19, 2025, at Florida International University campus in Miami, Fla. By Alie Skowronski NO. 4: WHAT A UNIVERSITY AND HOSPITAL PARTNERSHIP MEANS FOR HEALTHCARE IN MIAMI Here are five takeaways. | Published May 22, 2025 | Read Full Story by Miami Herald Archive, with AI summarization The summary above was drafted with the help of AI tools and edited by journalists in our News division. All stories listed were reported, written and edited by McClatchy journalists.
Yahoo
2 hours ago
- Yahoo
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional presentations highlight positive clinical and biomarker effects of zervimesine in the low p-tau217 population in Phase 2 Alzheimer's disease study - PURCHASE, N.Y., July 16, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that James E. Galvin, MD, MPH will present results from the Phase 2 'SHIMMER' study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the Alzheimer's Association International Conference (AAIC). Dr. Galvin is director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the COG1201 SHIMMER study (NCT05225415) director. The presentation will take place on July 29, 2025 in the 8:00 a.m. ET Featured Research Session. 'The results of the Phase 2 SHIMMER study give hope to the millions of people living with DLB and their healthcare teams, who struggle to treat this complex disease,' stated Dr. Galvin. 'My colleagues and I believe that there is great potential in a once-daily oral medication that slows disease progress while simultaneously reducing the severity and frequency of some of the most troublesome symptoms of DLB.' DLB is the second most common cause of dementia, affecting approximately 1.4 million Americans. People living with DLB experience a variety of symptoms, which typically include neuropsychiatric features such as hallucinations, delusions and agitation; cognitive impairment; Parkinsonian movement disorders; REM sleep behavior disorder; and fluctuations in attention and awareness. Currently no disease-modifying therapeutics are approved for DLB. Anthony Caggiano, MD, PhD, Cognition's CMO and head of R&D added, 'Zervimesine's broad neuroprotective mechanism is illustrated by the favorable results observed in the Phase 2 SHIMMER study in DLB. In the SHIMMER study, zervimesine treatment slowed the progression of DLB's diverse symptomology, with a meaningful impact on neuropsychiatric, motor, functional, and cognitive measures. Results from the Phase 2 'SHINE' study in people with Alzheimer's disease add further evidence to zervimesine's neuroprotective properties. We look forward to presenting results from both studies at AAIC.' The SHINE study was a signal-finding trial that showed zervimesine treatment preserved cognitive and functional abilities better than placebo in people with mild-to-moderate Alzheimer's disease. This impact was more robust in participants with lower levels of p-Tau217, who experienced a 95% slowing of cognitive decline at six months as measured by ADAS-Cog 11 compared to placebo. Cognition will present clinical efficacy results and new proteomic findings from this Alzheimer's study at AAIC. Dr. Galvin's slide presentation as well as Cognition's three posters will be available on the Cognition Therapeutics website in accordance with the conference's embargo policy. Cognition at AAIC: Featured Research Session: • Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812): 8:00-8:45 a.m. on July 29 Posters: • Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum: (#106858) July 27 • Exploratory CSF proteomic analysis of a pre-specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer's disease patients treated with zervimesine: (#102120) July 27 • An exploratory proteomics plasma biomarker analysis of the SHIMMER Phase 2 clinical trial to assess the pharmacodynamic effect of the sigma-2 receptor modulator zervimesine in dementia with Lewy bodies patients: (#106855) July 27 About the SHIMMER Study in Dementia with Lewy BodiesThe SHIMMER study (COG1201; NCT05225415) is an exploratory double-blind, placebo-controlled Phase 2 clinical trial that enrolled 130 adults with mild-to-moderate DLB, who were randomized to either daily oral doses of zervimesine (100 mg or 300 mg) or placebo for six months. A total of 88 participants were randomized to the two treatment arms and 42 to the placebo arm. Assessments were conducted throughout the study using a number of tools, including the Neuropsychiatric Inventory (NPI) to measure changes in hallucinations, anxiety and delusions; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research Battery (CDR), which track cognitive performance; and the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism. The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million (R01AG071643) and was conducted in collaboration with James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association (LBDA). About the SHINE Study in Mild-to-Moderate Alzheimer's Disease The SHINE study (NCT03507790) is a double-blind, placebo-controlled Phase 2 signal-finding trial that enrolled 153 adults with mild-to-moderate Alzheimer's disease who were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. The primary endpoint was safety and tolerability. The key secondary endpoint of cognition was ADAS-Cog 11. Exploratory endpoints included change in MMSE, ADAS-Cog 13, ADCS-ADL and -CGIC as well as pre-specified subgroup analyses included a comparison of cognitive and functional changes in participants with plasma p-tau217 levels above and below the median. The SHINE study was supported by two grant awards from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million. About Zervimesine (CT1812)Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer's disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person's ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer's and DLB. Zervimesine has been generally well tolerated in clinical studies to date. Zervimesine has been granted FDA Fast Track designation in Alzheimer's disease. The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812. About Cognition Therapeutics, Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease, including the ongoing START study (NCT05531656) in early Alzheimer's disease. We believe zervimesine and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases that are functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our future clinical development plans, and statements regarding our clinical trials of zervimesine and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information:Cognition Therapeutics, Casey McDonald (media)Tiberend Strategic Advisors, Mike Moyer (investors)LifeSci Advisorsmmoyer@ This press release was published by a CLEAR® Verified individual.
